This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

The pharmaceutical industry is undergoing a massive transformation. Historically slow to adopt technology, the industry is now undergoing rapid change as a result of the development of several technologies. Artificial intelligence (AI), additive manufacturing, blockchain, and other Industry 4.0 technologies are among the prominent pharma industry trends.

Among these, the US market is expected to grow at a 0-3% CAGR over the next five years, down from a 3% CAGR over the previous five years, and off-invoice discounts and rebates result in spending that is 31% lower than invoice level in 2020 and projected to be 36% lower than invoice level in 2025. 

Global spending on COVID-19 vaccines is expected to be $250 bn through 2026, though cost and volume estimates differ, and overall medicine spending is expected to exceed the pre-pandemic outlook by $133 bn through 2026 and grow at a 3-6% CAGR through 2026, reaching approximately $1.8 tn in total market size.

• Executive Summary
– Industry Overview
– Stock and Index Performance
– Leading Companies
– Regional Landscape
• CrispIdea Coverage:
– Abbott
– Abbvie
– Dr.Reddy
– Eli Lilly & Company
– Gilead Sciences
– Johnson & Johnson
– Merck & Co
– Moderna
– Novartis
– Pfizer
– Regeneron

This report was produced by a member company of the Crispidea. This report is for the use of intended recipients only and may not be reproduced (in whole or in part) or delivered or transmitted to any other person without our prior written consent. By accepting this report, the recipient agrees to be bound by the terms and limitations set out herein.